INCA33890 for Metastatic Cancer

Recruiting in Palo Alto (17 mi)

+37 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Recruiting

Sponsor: Incyte Corporation

Must not be taking: Systemic steroids, Anticoagulants

Disqualifiers: Other malignancy, Cardiac disease, others

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial is testing a new drug called INCA33890 to see if it is safe and how well patients can tolerate it. The study focuses on people with advanced or metastatic solid tumors, which are cancers that have spread and are hard to treat. Researchers aim to find the highest dose that can be given without causing serious side effects.

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. However, if you are on chronic systemic steroids or have recently changed anticoagulation therapies, you may not be eligible to participate.

What makes the drug INCA33890 unique for treating metastatic cancer?

INCA33890 is a novel treatment for metastatic cancer, but the provided research does not offer specific details about its unique features compared to existing treatments. It is important to consult clinical trial data or medical professionals for more information on its mechanism of action or benefits. ^{1 2 3 4 5}

Research Team

Eligibility Criteria

Adults with certain advanced or metastatic solid tumors who've had disease progression after standard treatments, including immunotherapies if applicable. They must have a good performance status, measurable disease, and be willing to undergo tumor biopsies. Exclusions include significant medical conditions, more than four prior cancer treatments for advanced disease, active infections or hepatitis/HIV, recent anticoagulation therapy changes.

Inclusion Criteria

I am 18 years old or older.

My cancer is confirmed to be advanced or has spread to other parts.

My cancer progressed after treatment, including immunotherapy, unless I couldn't tolerate it.

Exclusion Criteria

I am taking more than 10 mg/day of prednisone or its equivalent.

I am taking steroids for an autoimmune disease.

I am not on long-term antibiotics or drugs for a chronic infection.

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Dose Escalation

INCA33890 is administered intravenously at a starting regimen, with subsequent dose regimens determined during study conduct

8-12 weeks

Dose Expansion

INCA33890 is administered at the recommended dose(s) for expansion in participants with advanced or metastatic ICI sensitive or ICI non-sensitive tumor types

8-12 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

• INCA33890 (Other)

Trial Overview The trial is testing the safety of a new drug called INCA33890 in patients with specific types of solid tumors. It aims to find the maximum tolerated dose and optimal dosing schedule by observing any dose-limiting toxicities that occur during treatment.

Participant Groups

Group I: Part 1b-Dose Expansion Experimental Treatment 1 Intervention

INCA33890 will be administered at the recommended dose(s) for expansion (RDE\[s\]) in participants with advanced or metastatic ICI sensitive or ICI non sensitive tumor types

Group II: Part 1a - Dose Escalation Experimental Treatment 1 Intervention

INCA33890 will be administered at a protocol defined starting regimen intravenously. Subsequent dose regimens will be determined during study conduct.

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

Valkyrie Clinical Trials Los Angeles, CA

University of Pennsylvania Philadelphia, PA

Laura and Isaac Perlmutter Cancer Center New York, NY

Cancer and Hematology Centers of Western Michigan-Start Midwest Grand Rapids, MI

More Trial Locations

Who Is Running the Clinical Trial?

Incyte Corporation

Lead Sponsor

Trials

408

Patients Recruited

66,800+

Findings from Research

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Clinical endpoints for drug development in prostate cancer. Ramiah, V., George, DJ., Armstrong, AJ.[2015]

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Treatment strategies for advanced prostate cancer]. Küronya, Z., Bíró, K., Géczi, L., et al.[2021]

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Safety and tolerability of PCK3145, a synthetic peptide derived from prostate secretory protein 94 (PSP94) in metastatic hormone-refractory prostate cancer. Hawkins, RE., Daigneault, L., Cowan, R., et al.[2022]

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The association between measures of progression and survival in castrate-metastatic prostate cancer. Scher, HI., Warren, M., Heller, G.[2007]

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Novel therapeutics for the treatment of metastatic melanoma. Mansfield, AS., Markovic, SN.[2020]

References

1. United States pubmed.ncbi.nlm.nih.gov

Clinical endpoints for drug development in prostate cancer. [2015]

2. Hungary pubmed.ncbi.nlm.nih.gov

[Treatment strategies for advanced prostate cancer]. [2021]

3. United States pubmed.ncbi.nlm.nih.gov

Safety and tolerability of PCK3145, a synthetic peptide derived from prostate secretory protein 94 (PSP94) in metastatic hormone-refractory prostate cancer. [2022]

4. United States pubmed.ncbi.nlm.nih.gov

The association between measures of progression and survival in castrate-metastatic prostate cancer. [2007]

5. England pubmed.ncbi.nlm.nih.gov

Novel therapeutics for the treatment of metastatic melanoma. [2020]